HCV prodrug formulation

Details for Australian Patent Application No. 2006326130 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Birudaraj, Kondamraj; Shah, Navnit Hargovindas; Brandl, Michael Thomas; Stefanidis, Dimitrios; Ahmed, Hashim A.; Phuapradit, Wantanee; Alfredson, Thomas Vernon

Agent Spruson & Ferguson

Pub. Number AU-B-2006326130 (Modified Examination)

PCT Pub. Number WO2007/068615

Priority 60/830,594 12.07.06 US; 60/750,146 14.12.05 US

Filing date 4 December 2006

Wipo publication date 21 June 2007

Acceptance publication date 22 September 2011

International Classifications

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 9/50 (2006.01) Medicinal preparations characterised by special physical form - Microcapsules

A61K 31/70 (2006.01) - Carbohydrates

Event Publications

24 July 2008 PCT application entered the National Phase

  PCT publication WO2007/068615 Priority application(s): WO2007/068615

22 September 2011 Application Accepted

  Published as AU-B-2006326130 (Modified Examination)

19 January 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006326134-Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors

2006326070-Process for the purification of macrolide antibiotics